During clinical trials, patients must be informed about the composition of the hybrid hydrogel and clinicians must be clear about any missing information at the time of study that could potentially lead to unforeseen toxicity that could appear even late after treatment. Although aware of the need to closely follow up patients for any adverse effect, this introduces additional challenges in term of data management: who can access to the information (clinicians, researchers, insurance companies)? (ii) where to stock the information? and (iii) how to protect it from cyber-attacks? From an ethical point of view, we can also wonder whether the innovation brought by the hybrid hydrogels would widen the gap between high and low-income countries, further exacerbating inequities between two healthcare systems operating at different speeds. Solutions to address this potential disparity must be explored.